Published in Biochemistry on February 14, 2006
Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer. J Biol Chem (2012) 1.26
Ligand binding and hydration in protein misfolding: insights from studies of prion and p53 tumor suppressor proteins. Acc Chem Res (2010) 1.06
NetCSSP: web application for predicting chameleon sequences and amyloid fibril formation. Nucleic Acids Res (2009) 0.92
The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. Biophys J (2008) 0.90
Stability and structural recovery of the tetramerization domain of p53-R337H mutant induced by a designed templating ligand. Proc Natl Acad Sci U S A (2008) 0.89
p53 Aggregates penetrate cells and induce the co-aggregation of intracellular p53. PLoS One (2013) 0.86
p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene (2014) 0.84
Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor. Biosci Rep (2013) 0.84
A fluid salt-bridging cluster and the stabilization of p53. J Mol Biol (2007) 0.83
Potential roles for prions and protein-only inheritance in cancer. Cancer Metastasis Rev (2012) 0.82
An intrinsically disordered region of the acetyltransferase p300 with similarity to prion-like domains plays a role in aggregation. PLoS One (2012) 0.81
Regulation of p53 oligomerization by Ras superfamily protein RBEL1A. Genes Cancer (2015) 0.81
Cancer-associated p53 tetramerization domain mutants: quantitative analysis reveals a low threshold for tumor suppressor inactivation. J Biol Chem (2010) 0.80
Role of p53 isoforms and aggregations in cancer. Medicine (Baltimore) (2016) 0.79
Intermolecular β-strand networks avoid hub residues and favor low interconnectedness: a potential protection mechanism against chain dissociation upon mutation. PLoS One (2014) 0.75
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
All-atom empirical potential for molecular modeling and dynamics studies of proteins. J Phys Chem B (1998) 54.00
Structure validation by Calpha geometry: phi,psi and Cbeta deviation. Proteins (2003) 32.38
p53 mutations in human cancers. Science (1991) 31.96
p53, the cellular gatekeeper for growth and division. Cell (1997) 31.04
Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem (1989) 29.15
Prediction of protein conformation. Biochemistry (1974) 20.51
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
Protein folding and misfolding. Nature (2003) 14.92
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
The PredictProtein server. Nucleic Acids Res (2004) 10.89
Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. J Mol Med (Berl) (2003) 5.15
Rationalization of the effects of mutations on peptide and protein aggregation rates. Nature (2003) 4.98
A self-consistent method for the analysis of protein secondary structure from circular dichroism. Anal Biochem (1993) 4.85
Amyloid fibrillogenesis: themes and variations. Curr Opin Struct Biol (2000) 4.76
Review: protein secondary structure prediction continues to rise. J Struct Biol (2001) 3.91
Crystal structure of the tetramerization domain of the p53 tumor suppressor at 1.7 angstroms. Science (1995) 3.69
The structural basis of protein folding and its links with human disease. Philos Trans R Soc Lond B Biol Sci (2001) 3.65
Review: history of the amyloid fibril. J Struct Biol (2000) 3.49
Synthesis of a model protein of defined secondary and quaternary structure. Effect of chain length on the stabilization and formation of two-stranded alpha-helical coiled-coils. J Biol Chem (1984) 3.45
Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc Natl Acad Sci U S A (1994) 3.36
Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem (1989) 3.26
Identification and characterization of key kinetic intermediates in amyloid beta-protein fibrillogenesis. J Mol Biol (2001) 3.26
Alzheimer's amyloid fibrils: structure and assembly. Biochim Biophys Acta (2000) 3.20
An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A (2001) 3.14
Emerging ideas on the molecular basis of protein and peptide aggregation. Curr Opin Struct Biol (2003) 2.85
Refined solution structure of the oligomerization domain of the tumour suppressor p53. Nat Struct Biol (1995) 2.75
Trifluoroethanol and colleagues: cosolvents come of age. Recent studies with peptides and proteins. Q Rev Biophys (1998) 2.66
Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis (2001) 2.66
Solution structure of the tetrameric minimum transforming domain of p53. Nat Struct Biol (1994) 2.44
Prediction of amyloid fibril-forming proteins. J Biol Chem (2000) 2.12
HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41. Biochemistry (1996) 1.91
Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem (2003) 1.68
Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. Biochemistry (1997) 1.66
Kinetic studies of amyloid beta-protein fibril assembly. Differential effects of alpha-helix stabilization. J Biol Chem (2002) 1.61
High frequency of somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors. Oncogene (1992) 1.41
Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumour suppressor p53 tetramerization domain. EMBO J (1998) 1.39
Amyloid-fibril formation. Proposed mechanisms and relevance to conformational disease. Eur J Biochem (2002) 1.31
Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene (1998) 1.31
Defining the molecular basis of Arf and Hdm2 interactions. J Mol Biol (2001) 1.29
Characterization of p53 oligomerization domain mutations isolated from Li-Fraumeni and Li-Fraumeni like family members. Oncogene (1998) 1.28
Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution. Proc Natl Acad Sci U S A (1994) 1.25
Detecting hidden sequence propensity for amyloid fibril formation. Protein Sci (2004) 1.25
Fibrillar aggregates of the tumor suppressor p53 core domain. Biochemistry (2003) 1.22
Assembly of amyloid protofibrils via critical oligomers--a novel pathway of amyloid formation. J Mol Biol (2003) 1.17
Crystallization and structure solution of p53 (residues 326-356) by molecular replacement using an NMR model as template. Acta Crystallogr D Biol Crystallogr (1998) 1.12
Alternate aggregation pathways of the Alzheimer beta-amyloid peptide: Abeta association kinetics at endosomal pH. J Mol Biol (2003) 1.01
A new PRNP mutation (G131V) associated with Gerstmann-Sträussler-Scheinker disease. Arch Neurol (2001) 0.99
Comprehensive analysis of p53 gene mutation characteristics in lung carcinoma with special reference to histological subtypes. Int J Oncol (1999) 0.98
Reversible amyloid formation by the p53 tetramerization domain and a cancer-associated mutant. J Mol Biol (2003) 0.96
Amyloid fibrils from the viewpoint of protein folding. Cell Mol Life Sci (2004) 0.94
Probing the origins, diagnosis and treatment of amyloid diseases using antibodies. Biochimie (2004) 0.93
Rapid assessment of contact-dependent secondary structure propensity: relevance to amyloidogenic sequences. Proteins (2005) 0.92
Optimization of hydrophobic domains in peptides that undergo transformation from alpha-helix to beta-fibril. Bioorg Med Chem (1999) 0.88
Mutational analysis of designed peptides that undergo structural transition from alpha helix to beta sheet and amyloid fibril formation. Structure (2000) 0.88
Molecular determinants for amyloid fibril formation: lessons from lung surfactant protein C. Swiss Med Wkly (2003) 0.83
Function, oligomerization, and conformation of tumor-associated p53 proteins with mutated C-terminus. J Cell Biochem (2000) 0.82
Fibrinogen St. Gallen I (gamma 292 Gly--> Val): evidence for structural alterations causing defective polymerization and fibrinogenolysis. Thromb Haemost (1999) 0.76
Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A (2003) 9.14
p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat Cell Biol (2004) 5.82
Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell (2008) 5.11
Modern analytical ultracentrifugation in protein science: a tutorial review. Protein Sci (2002) 4.86
Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat Genet (2004) 3.89
Modulation of p53 function by SET8-mediated methylation at lysine 382. Mol Cell (2007) 3.68
Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat Cell Biol (2002) 3.55
Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J (2002) 3.45
Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nat Genet (2002) 3.32
MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J (2002) 3.29
Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab (2005) 3.15
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res (2008) 2.45
Studying multisite binary and ternary protein interactions by global analysis of isothermal titration calorimetry data in SEDPHAT: application to adaptor protein complexes in cell signaling. Protein Sci (2007) 2.44
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res (2003) 2.40
Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol Cell (2006) 2.39
Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proc Natl Acad Sci U S A (2003) 2.38
Posttranslational modification of p53: cooperative integrators of function. Cold Spring Harb Perspect Biol (2009) 2.34
Alternative p38 activation pathway mediated by T cell receptor-proximal tyrosine kinases. Nat Immunol (2005) 2.31
Oligomerization of signaling complexes by the multipoint binding of GRB2 to both LAT and SOS1. Nat Struct Mol Biol (2006) 2.10
Regulation of human Cdc25A stability by Serine 75 phosphorylation is not sufficient to activate a S phase checkpoint. Cell Cycle (2003) 2.10
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J Biol Chem (2003) 2.02
Distinct p53 genomic binding patterns in normal and cancer-derived human cells. Cell Cycle (2011) 2.01
A correlation between TCR Valpha docking on MHC and CD8 dependence: implications for T cell selection. Immunity (2003) 1.95
GSK-3 beta targets Cdc25A for ubiquitin-mediated proteolysis, and GSK-3 beta inactivation correlates with Cdc25A overproduction in human cancers. Cancer Cell (2008) 1.91
Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol (2009) 1.84
Structure of the Tfb1/p53 complex: Insights into the interaction between the p62/Tfb1 subunit of TFIIH and the activation domain of p53. Mol Cell (2006) 1.82
Membrane fusion. Chem Rev (2003) 1.69
Mutation of mouse p53 Ser23 and the response to DNA damage. Mol Cell Biol (2002) 1.65
Phosphorylation site interdependence of human p53 post-translational modifications in response to stress. J Biol Chem (2003) 1.63
Proteomic and bioinformatic characterization of the biogenesis and function of melanosomes. J Proteome Res (2006) 1.63
Relating molecular flexibility to function: a case study of tubulin. Biophys J (2002) 1.62
HIPK2 represses beta-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci U S A (2007) 1.58
Dual phosphorylation controls Cdc25 phosphatases and mitotic entry. Nat Cell Biol (2003) 1.58
Characterization of a new cancer-associated mutant of p53 with a missense mutation (K351N) in the tetramerization domain. Cell Cycle (2009) 1.57
ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem (2002) 1.56
Regulation of ATM/p53-dependent suppression of myc-induced lymphomas by Wip1 phosphatase. J Exp Med (2006) 1.53
Binding specificity of multiprotein signaling complexes is determined by both cooperative interactions and affinity preferences. Biochemistry (2004) 1.52
Mice deficient for the wild-type p53-induced phosphatase gene (Wip1) exhibit defects in reproductive organs, immune function, and cell cycle control. Mol Cell Biol (2002) 1.46
Cooperative interactions at the SLP-76 complex are critical for actin polymerization. EMBO J (2010) 1.45
The Epstein-Barr virus immediate-early protein BZLF1 regulates p53 function through multiple mechanisms. J Virol (2002) 1.45
Acetylation of mouse p53 at lysine 317 negatively regulates p53 apoptotic activities after DNA damage. Mol Cell Biol (2006) 1.45
Pillars article: Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992. 255: 1261-1263. J Immunol (2007) 1.39
Role for 53BP1 Tudor domain recognition of p53 dimethylated at lysine 382 in DNA damage signaling. J Biol Chem (2008) 1.38
Wip1 phosphatase regulates p53-dependent apoptosis of stem cells and tumorigenesis in the mouse intestine. Cell Stem Cell (2007) 1.37
The p53-induced oncogenic phosphatase PPM1D interacts with uracil DNA glycosylase and suppresses base excision repair. Mol Cell (2004) 1.36
Downstream E-box-mediated regulation of the human telomerase reverse transcriptase (hTERT) gene transcription: evidence for an endogenous mechanism of transcriptional repression. Mol Biol Cell (2002) 1.36
Diverse stresses dramatically alter genome-wide p53 binding and transactivation landscape in human cancer cells. Nucleic Acids Res (2013) 1.33
ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol Cell Biol (2005) 1.31
Proteomic analysis of early melanosomes: identification of novel melanosomal proteins. J Proteome Res (2003) 1.31
Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions. J Am Chem Soc (2006) 1.31
Structural basis for p300 Taz2-p53 TAD1 binding and modulation by phosphorylation. Structure (2009) 1.28
Regulation of tyrosinase processing and trafficking by organellar pH and by proteasome activity. J Biol Chem (2003) 1.27
Regulation of the Wip1 phosphatase and its effects on the stress response. Front Biosci (Landmark Ed) (2012) 1.24
Substrate specificity of the human protein phosphatase 2Cdelta, Wip1. Biochemistry (2005) 1.23
The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J Biol Chem (2002) 1.22
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest (2013) 1.21
Sorting of Pmel17 to melanosomes through the plasma membrane by AP1 and AP2: evidence for the polarized nature of melanocytes. J Cell Sci (2006) 1.20
A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J Immunol (2002) 1.19
Impairment of p53 acetylation, stability and function by an oncogenic transcription factor. EMBO J (2004) 1.16
Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol (2004) 1.15
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol (2010) 1.14
The MBT repeats of L3MBTL1 link SET8-mediated p53 methylation at lysine 382 to target gene repression. J Biol Chem (2010) 1.13
A decaepitope polypeptide primes for multiple CD8+ IFN-gamma and Th lymphocyte responses: evaluation of multiepitope polypeptides as a mode for vaccine delivery. J Immunol (2002) 1.13
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer. Cancer Cell (2006) 1.12
Multiple Chlamydia pneumoniae antigens prime CD8+ Tc1 responses that inhibit intracellular growth of this vacuolar pathogen. J Immunol (2002) 1.11
Improving the thermal, radial, and temporal accuracy of the analytical ultracentrifuge through external references. Anal Biochem (2013) 1.10
A model of voltage gating developed using the KvAP channel crystal structure. Biophys J (2004) 1.09
Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer. Cancer Res (2002) 1.09
Human apurinic/apyrimidinic endonuclease (Ape1) and its N-terminal truncated form (AN34) are involved in DNA fragmentation during apoptosis. J Biol Chem (2003) 1.08
Programmable multivalent display of receptor ligands using peptide nucleic acid nanoscaffolds. Nat Commun (2012) 1.06
Structural and functional insights into the HIV-1 maturation inhibitor binding pocket. PLoS Pathog (2012) 1.06
p53 N-terminal phosphorylation: a defining layer of complex regulation. Carcinogenesis (2012) 1.06
Interfacial water structure at polymer gel/quartz interfaces investigated by sum frequency generation spectroscopy. Phys Chem Chem Phys (2008) 1.06
Development of a substrate-based cyclic phosphopeptide inhibitor of protein phosphatase 2Cdelta, Wip1. Biochemistry (2006) 1.06
Hormone-dependent nuclear export of estradiol receptor and DNA synthesis in breast cancer cells. J Cell Biol (2008) 1.05
Two distinct motifs within the p53 transactivation domain bind to the Taz2 domain of p300 and are differentially affected by phosphorylation. Biochemistry (2009) 1.05
Models of voltage-dependent conformational changes in NaChBac channels. Biophys J (2008) 1.05
The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases. Biochemistry (2007) 1.04
Comparative Bioinformatics Analyses and Profiling of Lysosome-Related Organelle Proteomes. Int J Mass Spectrom (2007) 1.04